1、Sizing the brainSegmentation and growth factors of the global neuroscience marketDeloitte Switzerlands Corporate Finance Advisory team for Life Sciences and Health Care consists of specialists with extensive experience in sell-side advisory on company spin-offs,buy-side advisory on the acquisition o

2、r expansion of companies,as well as capital raising strategies.The team members have excellent connections within the Swiss economy,including life sciences startups and pharmaceutical companies,and specialists of Deloittes global network.Contact the authors to discuss tailor-made M&A or financing so

3、lutions in the context of mergers,acquisitions and divestitures,and debt or equity projects for life sciences and health care industries.Read more on DIntroduction 2Brain disorders and their impact on patients and society 3The findings 7Conclusion 20Endnotes 22Acknowledgements 24About the authors 24

4、Contact us 25ContentsACCORDING TO THE Global Burden of Disease,12 mental health disorders affect 970 million people globally.That is one in eight of the planets people.And the prevalence of these disorders has increased by 48%since 1990 as the population has grown.2Science should be coming to the re

5、scue,but innovations in neuroscience essentially stalled in the latter half of the last century.In the early 20th century,a combination of hard work and luck produced three broad types of psychiatric drugs:antidepressants,antipsychotics and anxiolytics.But psychopharmacology developments petered out

6、,and few new drugs reached the market during the last four decades.Further,the treatments on offer today often only delay the progression of the disease without recovering lost brain function.However,with advancements in brain disorders lagging behind treatments in other fields,such as cancer or tre